CN107428645A - 固体形式的还原甲萘醌 - Google Patents

固体形式的还原甲萘醌 Download PDF

Info

Publication number
CN107428645A
CN107428645A CN201680015954.7A CN201680015954A CN107428645A CN 107428645 A CN107428645 A CN 107428645A CN 201680015954 A CN201680015954 A CN 201680015954A CN 107428645 A CN107428645 A CN 107428645A
Authority
CN
China
Prior art keywords
menadione
formula
reduced
vitamin
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680015954.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·比安基
S·戴利
N·米拉利亚
A·特兰廷
F·科尔扎尼
F·博利尼
C·蓬佐内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gnosis SpA
Original Assignee
Gnosis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnosis SpA filed Critical Gnosis SpA
Publication of CN107428645A publication Critical patent/CN107428645A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/06—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation
    • C07C37/07—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by conversion of non-aromatic six-membered rings or of such rings formed in situ into aromatic six-membered rings, e.g. by dehydrogenation with simultaneous reduction of C=O group in that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/70—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment
    • C07C37/84—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment by crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
    • C07C39/225—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/66—Preparation of oxygen-containing organic compounds containing the quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/38—Pseudomonas
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680015954.7A 2015-03-20 2016-03-18 固体形式的还原甲萘醌 Pending CN107428645A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITUB20150528 2015-03-20
IT102015000009450 2015-03-20
PCT/IB2016/051528 WO2016151447A1 (en) 2015-03-20 2016-03-18 Solid forms of menaquinols

Publications (1)

Publication Number Publication Date
CN107428645A true CN107428645A (zh) 2017-12-01

Family

ID=53284441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680015954.7A Pending CN107428645A (zh) 2015-03-20 2016-03-18 固体形式的还原甲萘醌

Country Status (15)

Country Link
US (1) US10563270B2 (enExample)
EP (1) EP3270902A1 (enExample)
JP (1) JP2018514507A (enExample)
KR (1) KR20170128333A (enExample)
CN (1) CN107428645A (enExample)
AU (1) AU2016238473B2 (enExample)
BR (1) BR112017019750A2 (enExample)
CA (1) CA2979997A1 (enExample)
EA (1) EA032261B1 (enExample)
GE (1) GEP20197040B (enExample)
IL (1) IL254502B (enExample)
MX (1) MX2017011934A (enExample)
PH (1) PH12017501692A1 (enExample)
WO (1) WO2016151447A1 (enExample)
ZA (1) ZA201706282B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778092A (zh) * 2020-12-31 2021-05-11 玉溪健坤生物药业有限公司 一种还原型维生素k2的制备方法及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210018422A (ko) 2018-06-08 2021-02-17 에피존 파마 인코포레이티드 저항성칼슘형성의 예방 또는 치료를 위한 방법 및 조성물
JP2021527128A (ja) 2018-06-08 2021-10-11 エピゾン・ファーマ・インコーポレイテッドＥｐｉｚｏｎ Ｐｈａｒｍａ， Ｉｎｃ． 組織石灰化を予防または治療するための方法および組成物
CA3111108A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
EP4001421A1 (en) * 2020-11-16 2022-05-25 Endektovet Ltd Method for obtaining oil extract of menaquinone-7 from fermentation broth
CN115304464B (zh) * 2022-09-02 2023-03-14 新拓洋生物工程有限公司 一种维生素k2（35）的提取方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003137716A (ja) * 2001-10-30 2003-05-14 Eau De Faveur:Kk 皮膚の外用剤
JP2006083132A (ja) * 2004-09-17 2006-03-30 Kaneka Corp 還元型ビタミンｋの製造方法
WO2009062662A1 (en) * 2007-11-16 2009-05-22 Gnosis S.P.A. Pharmaceutical and nutraceutical compositions based on menaquinols
CN103687495A (zh) * 2011-05-20 2014-03-26 弗里斯兰品牌有限公司 包含维生素k2的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310029B (enExample) * 2001-07-13 2009-05-21 Kaneka Corp
TWI329510B (en) * 2001-10-10 2010-09-01 Kaneka Corp Method of stabilizing reduced coenzyme q10

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003137716A (ja) * 2001-10-30 2003-05-14 Eau De Faveur:Kk 皮膚の外用剤
JP2006083132A (ja) * 2004-09-17 2006-03-30 Kaneka Corp 還元型ビタミンｋの製造方法
WO2009062662A1 (en) * 2007-11-16 2009-05-22 Gnosis S.P.A. Pharmaceutical and nutraceutical compositions based on menaquinols
CN103687495A (zh) * 2011-05-20 2014-03-26 弗里斯兰品牌有限公司 包含维生素k2的组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ISLER等: "Synthese and Isolierung von Vitamin K2 and isoprenologen Verbindungenl", 《HELVETICA CHIMICA ACTA 》 *
杨灵莉: "维生素K2的合成方法研究", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 *
陶轶等: "维生素K2类化合物合成研究进展", 《化学通报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778092A (zh) * 2020-12-31 2021-05-11 玉溪健坤生物药业有限公司 一种还原型维生素k2的制备方法及其用途
CN112778092B (zh) * 2020-12-31 2023-03-24 玉溪健坤生物药业有限公司 一种还原型维生素k2的制备方法及其用途

Also Published As

Publication number Publication date
US20180066326A1 (en) 2018-03-08
MX2017011934A (es) 2018-02-09
ZA201706282B (en) 2019-01-30
WO2016151447A1 (en) 2016-09-29
JP2018514507A (ja) 2018-06-07
CA2979997A1 (en) 2016-09-29
EA201791845A1 (ru) 2018-02-28
KR20170128333A (ko) 2017-11-22
EA032261B1 (ru) 2019-04-30
IL254502A0 (en) 2017-11-30
AU2016238473B2 (en) 2020-03-12
US10563270B2 (en) 2020-02-18
GEP20197040B (en) 2019-11-11
AU2016238473A1 (en) 2017-08-24
IL254502B (en) 2020-09-30
PH12017501692A1 (en) 2018-03-19
EP3270902A1 (en) 2018-01-24
BR112017019750A2 (pt) 2018-05-29

Similar Documents

Publication Publication Date Title
CN107428645A (zh) 固体形式的还原甲萘醌
HUE026507T2 (hu) Enzimatikus eljárás kortexolon-17-propionát IV-es hidrát kristályformában történõ elõállítására
AU2006251803A8 (en) Derivatives of 4-or 5-aminosalicylic acid
JPWO2001053290A1 (ja) 細胞分裂阻害剤及びその製造方法
EP0313874B1 (en) Disulfur analogs of LL-E33288 antitumor agents
HU229102B1 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
Karginov et al. β-Cyclodextrin derivatives that inhibit anthrax lethal toxin
RU2653497C2 (ru) Производные пантотената для лечения неврологических заболеваний
FR2780649A1 (fr) Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine
US9981985B2 (en) Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin SV and 3-formylrifamycin S and a process of their preparation
ZA200108627B (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments.
CN110407765A (zh) 1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
EP2084125B1 (fr) Derives d'aminobenzocycloheptene, leurs procedes de preparation et leur utilisation en therapeutique
EP0772630B1 (fr) Derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1995028929A1 (en) Aminoline-n-oxide antimicrobials for use against h. pylori infections
CN113396214B (zh) 从链霉菌属sp.mcc 0151生产尼日利亚菌素的方法
Tribak et al. N-alkylation methods, Characterization and Evaluation of antibacterial activity of some Novel 5-Chloroisatin Derivatives
EP3021669B1 (fr) Nouveaux composes dérivés de la solanidine
JP2000239266A (ja) 新規ポリエン系抗生物質
JPH09176075A (ja) 抗菌・抗カビ・抗炎症活性物質とその製造方法
CN1451314A (zh) 环糊精衍生物在饮料中的应用
FR2464265A1 (fr) Nouvelle substance antibiotique a base de dihydro-3,4 hydroxy-4(hydroxy-3 pyridyl-2)-5 methyl-4 2h-pyrrolecarboxamide-2, utile notamment comme medicament et procede de sa preparation utilisant une nouvelle souche de micro-organisme
JP3616656B2 (ja) ラン藻由来の抗カビ活性剤およびその製造方法
KR100673570B1 (ko) 토양 방선균 ｋａｃｃ91015 배양액으로부터 순수 분리된 ｆ4-2-4 및 그 제조 방법과 약제학적 조성물
KR20160070460A (ko) 루비프로스톤의 정제방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171201